Recently, glucagon-like peptide-1 receptor agonists (GLP-1 RAs), a class of antidiabetic and anti-obesity medications, have gained growing emphasis in the management of obesity and overweight, as well as coexisting weight-related conditions (5-7). This evidence concerns the gene GLP1R and obesity disorder.